Earnings Call Summary | NUMINUS WELLNESS INC(NUMIF.US) Q2 2024 Earnings Conference
Earnings Call Summary | NUMINUS WELLNESS INC(NUMIF.US) Q2 2024 Earnings Conference
The following is a summary of the Numinus Wellness Inc. (NUMIF) Q2 2024 Earnings Call Transcript:
以下是Numinus Wellness Inc.（NUMIF）2024年第二季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Numinus reported Q2 2024 revenue of $5 million, down from $5.9 million in the previous quarter.
The revenue generated from wellness clinics fell by 9.5% year-over-year to $4.3 million.
There was a dip in the gross margin which decreased from the previous quarter's 36.1% to 33%.
U.S. operations generated the majority of the total revenue, accounting for 87%.
Numinus報告稱，2024年第二季度收入爲500萬美元，低於上一季度的590萬美元。
健康診所產生的收入同比下降9.5％，至430萬美元。
毛利率有所下降，從上一季度的36.1％下降至33％。
美國業務佔總收入的大部分，佔87％。
Business Progress:
業務進展：
The company is channeling its focus on growth in the U.S. while providing support to Canadian organizations through a more resource-efficient model.
Numinus played a key role in providing the highest enrolling sites for MM120 clinical trials, and is now getting ready to become a research partner in Phase 3 trials.
A new membership program is being launched by Numinus for Canadian therapists and healthcare professionals to keep them updated with the latest therapeutic protocols.
There has been a significant reduction in the company's headcount, with a 60% reduction since Q2 2023, as the company focuses on cost-cutting measures and revenue-generating roles.
Numinus has decided to close its unprofitable clinic in Phoenix, Arizona and the Numinus Bioscience business, opting instead to focus on profitable operations in the U.S.
該公司正在將重點放在美國的增長上，同時通過更節約資源的模式爲加拿大組織提供支持。
Numinus 在爲 MM120 臨床試驗提供最高註冊場所方面發揮了關鍵作用，現在正準備成爲 3 期試驗的研究合作伙伴。
Numinus正在爲加拿大治療師和醫療保健專業人員推出一項新的會員計劃，以使他們隨時了解最新的治療方案。
由於公司專注於削減成本的措施和創收職位，該公司的員工人數已大幅減少，自2023年第二季度以來減少了60％。
Numinus已決定關閉其位於亞利桑那州鳳凰城的無利可圖的診所和Numinus Bioscience業務，而是選擇專注於在美國的盈利業務。
More details: NUMINUS WELLNESS INC IR
更多詳情： NUMINUS WELLNESS INC
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。